Prostate cancer is the most common cancer to affect men in the United States and the second most common cancer in men worldwide. Prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET) imaging is gradually recognized as a novel technique that can improve treatment decisions and affect clinical care of prostate cancer patients as the PSMA expression in most prostate malignant cells correlates well with serum prostate-specific antigen concentration.